{
    "info": {
        "nct_id": "NCT04719273",
        "official_title": "A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer",
        "inclusion_criteria": "* Age greater than or equal to 18 years old\n* Histologically confirmed diagnosis of endometrial cancer with ER and/or PR expression >= 1% by IHC on archival tissue taken within the prior 3 years or new biopsy if no archival tissue is available. IHC results do not have to be from Thomas Jefferson University\n* Patients who have failed one prior treatment with a platinum/taxane chemotherapy regimen for management of disease\n\n  * Patients cannot have treatment with more than 2 prior lines of therapy (one line must be platinum/taxane regimen)\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension. Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI\n* Patients with the following histologic epithelial cell types are eligible:\n\n  * Endometrioid adenocarcinoma\n  * Serous adenocarcinoma\n  * Undifferentiated carcinoma\n  * Clear cell adenocarcinoma\n  * Mixed epithelial carcinoma\n  * Adenocarcinoma not otherwise specified (NOS)\n  * Please note: patients with carcinosarcoma are ineligible for this trial\n* Patients must have had one prior treatment with a platinum/taxane chemotherapy regimen for management of disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Must have a life expectancy of at least 12 weeks as judged by the treating physician\n* Females are only eligible for this study if they are postmenopausal. This is defined as meeting one of the following criteria:\n\n  * S/p total abdominal hysterectomy and bilateral salpingo-oopherectomy\n  * Patients who are in menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 55 in the absence of other biological or physiological causes OR women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.\n* Body weight > 30 kg\n* Absolute neutrophil count 1500/ul or more\n* Platelets 100,000/ul or more\n* Hemoglobin 9 g/dl or more\n* Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)\n* Endocrine and targeted therapy protocols usually enroll patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) in patients without underlying liver metastasis and < 5.0 x ULN in patients with underlying liver metastasis\n* Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula or measured creatinine clearance using 24 hours urine collection\n* International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n* All subjects must be able to comprehend and sign a written informed consent document\n* Resolution of all acute toxic effects of prior therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) grade =< 1, with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowed\n* Patient has recovered from any prior radiotherapy\n* Patients must be able to swallow tablets whole, without crushing\n* Be able to read and speak English\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Concurrent or recent chemotherapy, radiotherapy, immunotherapy, or general anesthesia/major surgery within 3 weeks\n* History of prior hormonal therapy (i.e., megestrol acetate, tamoxifen or aromatase inhibitors) for treatment cancer within the past 2 months. Other concurrent hormonal therapy will not be allowed on this trial\n* Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy\n* If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment\n* Has received prior systemic anti-cancer therapy including investigational agents within 3 weeks prior to randomization\n* Known brain metastasis which have not been treated or showed stability for >= 6 months\n* Proteinuria > 1+ on urinalysis or > 1 gm/24 hours (hr)\n* Known history of New York Heart Association stage 3 or 4 cardiac disease\n* A pleural or pericardial effusion of greater than or equal to grade 3 severity\n* Women who are pregnant or nursing\n* Has an active infection requiring systemic therapy\n* Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity; specifically strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4\n* Patients may not be on a concurrent clinical trial, unless approved by investigator",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* All subjects must be able to comprehend and sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "must be able to comprehend ... informed consent document",
                    "criterion": "comprehension of informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be able to ... sign a written informed consent document",
                    "criterion": "ability to sign informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adenocarcinoma not otherwise specified (NOS)",
            "criterions": [
                {
                    "exact_snippets": "Adenocarcinoma not otherwise specified (NOS)",
                    "criterion": "adenocarcinoma (not otherwise specified)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Please note: patients with carcinosarcoma are ineligible for this trial",
            "criterions": [
                {
                    "exact_snippets": "patients with carcinosarcoma are ineligible",
                    "criterion": "carcinosarcoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count 1500/ul or more",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count 1500/ul or more",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Mixed epithelial carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Mixed epithelial carcinoma",
                    "criterion": "mixed epithelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Endometrioid adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Endometrioid adenocarcinoma",
                    "criterion": "endometrioid adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Body weight > 30 kg",
            "criterions": [
                {
                    "exact_snippets": "Body weight > 30 kg",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets 100,000/ul or more",
            "criterions": [
                {
                    "exact_snippets": "Platelets 100,000/ul or more",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Undifferentiated carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Undifferentiated carcinoma",
                    "criterion": "undifferentiated carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has recovered from any prior radiotherapy",
            "criterions": [
                {
                    "exact_snippets": "Patient has recovered from any prior radiotherapy",
                    "criterion": "recovery from prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "recovered"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age greater than or equal to 18 years old",
            "criterions": [
                {
                    "exact_snippets": "Age greater than or equal to 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Be able to read and speak English",
            "criterions": [
                {
                    "exact_snippets": "Be able to read ... English",
                    "criterion": "English reading ability",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Be able to ... speak English",
                    "criterion": "English speaking ability",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin 9 g/dl or more",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin 9 g/dl or more",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clear cell adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Clear cell adenocarcinoma",
                    "criterion": "clear cell adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serous adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Serous adenocarcinoma",
                    "criterion": "serous adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with the following histologic epithelial cell types are eligible:",
            "criterions": [
                {
                    "exact_snippets": "histologic epithelial cell types",
                    "criterion": "histologic epithelial cell type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "epithelial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females are only eligible for this study if they are postmenopausal. This is defined as meeting one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Females are only eligible for this study if they are postmenopausal",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "Females are only eligible for this study if they are postmenopausal",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "postmenopausal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have had one prior treatment with a platinum/taxane chemotherapy regimen for management of disease",
            "criterions": [
                {
                    "exact_snippets": "one prior treatment with a platinum/taxane chemotherapy regimen",
                    "criterion": "prior platinum/taxane chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "number of prior treatments",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "platinum chemotherapy",
                                "taxane chemotherapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to swallow tablets whole, without crushing",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to swallow tablets whole, without crushing",
                    "criterion": "ability to swallow tablets whole",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "without crushing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula or measured creatinine clearance using 24 hours urine collection",
            "criterions": [
                {
                    "exact_snippets": "Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula",
                    "criterion": "glomerular filtration rate (GFR) (Cockcroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measured creatinine clearance using 24 hours urine collection",
                    "criterion": "measured creatinine clearance (24 hours urine collection)",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": "performed"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have failed one prior treatment with a platinum/taxane chemotherapy regimen for management of disease",
            "criterions": [
                {
                    "exact_snippets": "failed one prior treatment with a platinum/taxane chemotherapy regimen",
                    "criterion": "prior platinum/taxane chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "number of prior treatments failed",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "platinum chemotherapy",
                                "taxane chemotherapy"
                            ]
                        },
                        {
                            "requirement_type": "treatment outcome",
                            "expected_value": "failed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients cannot have treatment with more than 2 prior lines of therapy (one line must be platinum/taxane regimen)",
            "criterions": [
                {
                    "exact_snippets": "Patients cannot have treatment with more than 2 prior lines of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one line must be platinum/taxane regimen",
                    "criterion": "prior therapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "at least one prior line must be a platinum/taxane regimen"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Resolution of all acute toxic effects of prior therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) grade =< 1, with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowed",
            "criterions": [
                {
                    "exact_snippets": "Resolution of all acute toxic effects of prior therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) grade =< 1",
                    "criterion": "acute toxic effects of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowed",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowed",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* S/p total abdominal hysterectomy and bilateral salpingo-oopherectomy",
            "criterions": [
                {
                    "exact_snippets": "S/p total abdominal hysterectomy",
                    "criterion": "total abdominal hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bilateral salpingo-oopherectomy",
                    "criterion": "bilateral salpingo-oopherectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin less than or equal to 1.5 x the upper limit of normal",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl",
                    "criterion": "total bilirubin in subjects with Gilbert syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have a life expectancy of at least 12 weeks as judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of at least 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as judged by the treating physician",
                    "criterion": "treating physician judgment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are in menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 55 in the absence of other biological or physiological causes OR women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.",
            "criterions": [
                {
                    "exact_snippets": "menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 55 in the absence of other biological or physiological causes",
                    "criterion": "menopause status",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "12 consecutive months of amenorrhea in a woman over 55 in the absence of other biological or physiological causes"
                        }
                    ]
                },
                {
                    "exact_snippets": "woman over 55",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL",
                    "criterion": "serum follicle stimulating hormone (FSH) level",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "women under the age of 55",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum age",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension. Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1.",
                    "criterion": "measurable disease (RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one lesion that can be accurately measured in at least one dimension",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "number of measurable lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability in one dimension",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI)",
                    "criterion": "lesion size (by CT or MRI)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "measurement modality",
                            "expected_value": [
                                "CT",
                                "MRI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI",
                    "criterion": "lymph node size (short axis, by CT or MRI)",
                    "requirements": [
                        {
                            "requirement_type": "size (short axis)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "measurement modality",
                            "expected_value": [
                                "CT",
                                "MRI"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed diagnosis of endometrial cancer with ER and/or PR expression >= 1% by IHC on archival tissue taken within the prior 3 years or new biopsy if no archival tissue is available. IHC results do not have to be from Thomas Jefferson University",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed diagnosis of endometrial cancer",
                    "criterion": "endometrial cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ER and/or PR expression >= 1% by IHC",
                    "criterion": "ER and/or PR expression",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "by IHC on archival tissue taken within the prior 3 years or new biopsy if no archival tissue is available",
                    "criterion": "tissue sample for IHC",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "archival tissue taken within the prior 3 years",
                                "new biopsy if no archival tissue is available"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "IHC results do not have to be from Thomas Jefferson University",
                    "criterion": "IHC testing location",
                    "requirements": [
                        {
                            "requirement_type": "location restriction",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "INR, PT, aPTT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Women who are pregnant or nursing",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may not be on a concurrent clinical trial, unless approved by investigator",
            "criterions": [
                {
                    "exact_snippets": "Patients may not be on a concurrent clinical trial, unless approved by investigator",
                    "criterion": "concurrent clinical trial participation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless approved by investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Has an active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of New York Heart Association stage 3 or 4 cardiac disease",
            "criterions": [
                {
                    "exact_snippets": "Known history of New York Heart Association stage 3 or 4 cardiac disease",
                    "criterion": "New York Heart Association cardiac disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Proteinuria > 1+ on urinalysis or > 1 gm/24 hours (hr)",
            "criterions": [
                {
                    "exact_snippets": "Proteinuria > 1+ on urinalysis",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "test",
                            "expected_value": "urinalysis"
                        }
                    ]
                },
                {
                    "exact_snippets": "Proteinuria ... > 1 gm/24 hours (hr)",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "gm/24 hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "received major surgery",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment",
                    "criterion": "recovery from surgery toxicity and/or complications",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy",
            "criterions": [
                {
                    "exact_snippets": "Patient has a concurrent malignancy",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of invasive malignancy within 3 years of enrollment",
                    "criterion": "history of invasive malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy",
                    "criterion": "type of malignancy exception",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "basal cell skin cancer",
                                "squamous cell skin cancer",
                                "superficial bladder cancer",
                                "carcinoma in situ of the cervix (with completed curative therapy)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known brain metastasis which have not been treated or showed stability for >= 6 months",
            "criterions": [
                {
                    "exact_snippets": "Known brain metastasis",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "which have not been treated",
                    "criterion": "brain metastasis treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "not treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "or showed stability for >= 6 months",
                    "criterion": "brain metastasis stability",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of prior hormonal therapy (i.e., megestrol acetate, tamoxifen or aromatase inhibitors) for treatment cancer within the past 2 months. Other concurrent hormonal therapy will not be allowed on this trial",
            "criterions": [
                {
                    "exact_snippets": "History of prior hormonal therapy (i.e., megestrol acetate, tamoxifen or aromatase inhibitors) for treatment cancer within the past 2 months",
                    "criterion": "prior hormonal therapy for cancer",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Other concurrent hormonal therapy will not be allowed on this trial",
                    "criterion": "concurrent hormonal therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent_use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior systemic anti-cancer therapy including investigational agents within 3 weeks prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Has received prior systemic anti-cancer therapy including investigational agents within 3 weeks prior to randomization",
                    "criterion": "prior systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior systemic anti-cancer therapy including investigational agents within 3 weeks prior to randomization",
                    "criterion": "prior investigational agent therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent or recent chemotherapy, radiotherapy, immunotherapy, or general anesthesia/major surgery within 3 weeks",
            "criterions": [
                {
                    "exact_snippets": "Concurrent or recent chemotherapy ... within 3 weeks",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent or recent ... radiotherapy ... within 3 weeks",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent or recent ... immunotherapy ... within 3 weeks",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent or recent ... general anesthesia/major surgery within 3 weeks",
                    "criterion": "general anesthesia/major surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A pleural or pericardial effusion of greater than or equal to grade 3 severity",
            "criterions": [
                {
                    "exact_snippets": "A pleural or pericardial effusion of greater than or equal to grade 3 severity",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "A pleural or pericardial effusion of greater than or equal to grade 3 severity",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity; specifically strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4",
            "criterions": [
                {
                    "exact_snippets": "Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity",
                    "criterion": "prescription medication use",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "investigator judgment of interference with onapristone activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "specifically strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4",
                    "criterion": "use of strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
            "criterions": []
        },
        {
            "line": "* Endocrine and targeted therapy protocols usually enroll patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) in patients without underlying liver metastasis and < 5.0 x ULN in patients with underlying liver metastasis",
            "criterions": [
                {
                    "exact_snippets": "aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) in patients without underlying liver metastasis",
                    "criterion": "AST/ALT levels in patients without underlying liver metastasis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5.0 x ULN in patients with underlying liver metastasis",
                    "criterion": "AST/ALT levels in patients with underlying liver metastasis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}